Document:

<PAGE>

                                                                   Exhibit 10.10

                                             (OMRIX BIOPHARMACEUTICALS(TM) LOGO)
                                                    innovative solutions
                                                    for a healthier world

August 10, 2006

Mr. Patrick Schmidt
FFF Enterprises, Inc.
41093 County Center Drive
Temecula, CA 92651

     Re: Supply And Distribution Agreement: Investigational Phase between Omrix
         biopharmaceuticals, Ltd. and FFF Enterprises, Inc., dated as of
         December 21, 2005 (the "Agreement")

Dear Pat:

To date, the FDA has not approved the Treatment Protocol and the Treatment
Protocol Charge Price for Omrigam NF. Nevertheless, FFF and Omrix have agreed to
conduct the Phase 3 Clinical Trial in accordance with Section 4.2.c.2 of the
Agreement, as modified by the following terms:

     1.   FFF commits to complete the Phase 3 Clinical Trial independent of
          receiving an approval for the Treatment Protocol and Treatment
          Protocol Charge Price.

     2.   FFF will continue to attempt to obtain approval from the FDA for
          Treatment Protocol and Treatment Protocol Charge Price during the
          Phase 3 Clinical Trial.

     3.   Omrix commits to supply FFF with Omrigam NF manufactured from source
          plasma in the amount required for the Phase 3 Clinical Trial.

     4.   Omrix will invoice and FFF will pay the Treatment Protocol Purchase
          Price (*** per gram) for the Omrigam NF supplied for the purpose of
          the Phase 3 Clinical Trial. FFF will pay this amount notwithstanding
          the provisions of Section 4.3.a of the Agreement. Payment will be due
          within 30 days from the date of shipping. The cost of purchasing
          Omrigam NF under this letter shall not be included in the calculation
          of FFF's out-of-pocket expenses for conducting the Clinical Trials
          under Section 15.3.a of the Agreement.

     5.   If FFF receives approval of a Treatment Protocol from the FDA, Omrix
          will credit FFF for the Treatment Protocol Purchase Price charged by
          Omrix for Omrigam NF supplied by Omrix for the Phase 3 Clinical Trial
          prior to the receipt of a Treatment Protocol (the "Credit Amount").
          The credit will be applied against purchases of Omrigam NF made under
          the Treatment Protocol up to the Credit Amount.

                          OMRIX biopharmaceuticals Ltd.

PORTIONS OF THIS EXHIBIT MARKED BY AN *** HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.
<PAGE>

                                             (OMRIX BIOPHARMACEUTICALS(TM) LOGO)
                                                    innovative solutions
                                                    for a healthier world

     6.   The parties agree that approval of a Treatment Protocol shall no
          longer be a basis for termination of the Agreement. Accordingly,
          Section 15.2.b to the Agreement is amended to delete "If the Treatment
          Protocol is not approved within two (2) months from when the Treatment
          Protocol was received by the FDA; or" to read in its entirety: "If the
          Treatment Protocol is approved by the FDA and (i) approval is
          subsequently revoked or (ii) the Treatment Protocol is placed on
          clinical hold and the Treatment Protocol cannot be reinstated without
          undue hardship to either Party;".

     7.   The parties agree that the Treatment Protocol will only apply to
          primary immune deficiency. Accordingly, in the 1st sentence of the
          definition of Treatment Protocol, in Section 1.26 of the Agreement,
          the following words are deleted: "and other immune diseases" and the
          4th sentence in Section 2.10 of the Agreement shall be revised to
          read: "In the event the FDA approves the use of the Investigational
          Drug in the Treatment Protocol for primary immune deficiency, the
          first payment will commence..."

     8.   As applicable to clause (iii) of Section 15.3d of the Agreement, the
          applicable date shall be changed from September 1, 2007 to 12 months
          from approval of the Treatment Protocol.

     9.   Clause (b) of Section 15.3(e) of the Agreement shall be changed from
          "up to a maximum amount of *** for the Investigational Drug
          supplied by Omrix for the Clinical Trials at the Treatment Protocol
          Purchase Price" to the amount of the Credit Amount applied against
          purchases of Omrigam NF made by FFF under the Treatment Protocol.

This letter is issued under the Agreement, and except as modified herein, the
Agreement continues in full force. All terms capitalized in this letter, not
otherwise defined herein, shall have the meaning set forth in the Agreement.

Please sign below, and return copy to Omrix, to indicate FFF's agreement to the
terms of this letter.

Very truly yours,

/s/ Robert Taub
-------------------------------------
Robert Taub

FFF Enterprises, Inc.

By: /s/ Pat Schmidt
    ---------------------------------
Name:
      -------------------------------
Title:
       ------------------------------
Date:
      -------------------------------

                          OMRIX biopharmaceuticals Ltd.<PAGE>
                                                                   Exhibit 10.11

            SUPPLY AND DISTRIBUTION AGREEMENT: INVESTIGATIONAL PHASE

THIS AGREEMENT (the "AGREEMENT") is entered into by and between OMRIX
BIOPHARMACEUTICALS, LTD., an Israeli company (hereinafter, "OMRIX"), and FFF
ENTERPRISES, INC., a United States ("US") corporation organized and existing
under the laws of California (hereinafter, "FFF") together with Omrix, the
"PARTIES" and each individually a "PARTY," as of December 21, 2005 (the
"EFFECTIVE DATE").

WHEREAS:

A.   Omrix manufactures Omrigam NF, a proprietary immune globulin intravenous
     (IGIV), which has not been cleared by the United States (US) Food and Drug
     Administration (FDA) for marketing in the US;

B.   Omrix wishes to obtain FDA approval of a Biologics License Application
     (BLA) to market Omrigam NF in the US;

C.   Omrix is the sponsor of an active Investigational New Drug Application
     (hereinafter "OMRIX IND") to use Omrigam NF in clinical trials of patients
     with primary immune deficiency (hereinafter "CLINICAL TRIALS");

D.   FFF is a wholesale distributor of pharmaceutical products, including IGIV
     products, in the US and wishes to be the exclusive distributor of Omrigam
     NF in the US;

E.   FFF wishes to take over sponsorship of the amended Omrix IND (referred to
     as the FFF IND);

F.   FFF also wishes to be responsible for conducting the Clinical Trials and
     Omrix will use the data collected in the Clinical Trials to prepare a
     Biologics License Application ("BLA") to submit to the FDA under Omrix's
     name to market Omrigam NF commercially in the US;

G.   FFF wishes to distribute Omrigam NF in the US under a TREATMENT PROTOCOL,
     as defined below, until the BLA is approved by the FDA;

H.   FFF will conduct both the Clinical Trials and the Treatment Protocol under
     the FFF IND ;

I.   Omrix wishes to supply Omrigam NF exclusively to FFF for use in the
     Clinical Trials and under a Treatment Protocol (collectively the
     "INVESTIGATIONAL PHASE");

J.   Omrix wishes to designate FFF as its exclusive authorized distributor to
     market Omrigam NF in the US subsequent to FDA approval of the BLA for
     Omrigam NF (the "COMMERCIAL PHASE," as defined in section 1.5, below); and

K.   Simultaneous execution of the agreement between the Parties for the
     Commercial Phase, SUPPLY AND DISTRIBUTION AGREEMENT: COMMERCIAL PHASE,
     attached hereto as Exhibit A) is a concurrent condition to the complete
     execution of this Agreement:

NOW, THEREFORE, in consideration of the mutual promises and covenants contained
herein, effective upon the Effective Date, the Parties agree as follows:

1.   DEFINITIONS

As used in this Agreement the following definitions shall apply in each case
where the defined term appears in capitalized form:

     1.1. "BLA" - means a Biologics License Application, as defined in 21 CFR
          Section 601.2.

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL      Page 1 of 27

PORTIONS OF THIS EXHIBIT MARKED BY AN *** HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.
<PAGE>

     1.2. "CFR" - means the U.S. Code of Federal Regulations, as may be amended
          from time to time, and any successor thereto.

     1.3. "CGMP" - means current Good Manufacturing Practices and General
          Biological Products Standards as defined in 21 CFR Parts 210, 211 and
          600 and 606.

     1.4. "CLINICAL TRIALS" - means the Phase 2 and the Phase 3 Clinical Trials,
          as defined below.

     1.5. "COMMERCIAL PHASE" - means the phase of a relationship between the
          Parties after FDA approval of a Biologics License Application has been
          obtained and Omrigam NF may be marketed in the U.S. The agreement
          between the Parties for FFF to be the exclusive distributor of Omrigam
          NF for the Commercial Phase is attached hereto as Exhibit A (SUPPLY
          AND DISTRIBUTION AGREEMENT: COMMERCIAL PHASE).

     1.6. "DATA" - means data collected in the Clinical Trials.

     1.7. "DCI" - means DCI Management Group, LLC.

     1.8. "DCI CONTRACT" - means the Plasma Supply Agreement between Omrix and
          DCI Management Group, LLC, attached hereto as Exhibit B, execution of
          which is a condition precedent to this Agreement.

     1.9. "FDA" - means the US Food and Drug Administration.

     1.10. "FFF IND" -- means the Investigational New Drug Application approved
          by the FDA and held by FFF for Omrigam NF. This is the amended version
          of the Omrix IND

     1.11. "IGIV" - means immune globulin intravenous.

     1.12. "IND" - means an Investigational New Drug Application, as described
          in 21 CFR Part 312.

     1.13. "INSTITUTIONAL REVIEW BOARD" (IRB) - means the committee responsible
          for reviewing and approving biomedical research involving human
          subjects, as described in 21 CFR 50.3(i).

     1.14. "INVESTIGATIONAL DRUG" - means cGMP quality Omrigam NF prior to
          approval by the FDA of a Biologics License Application.

     1.15. "INVESTIGATIONAL PHASE" - means the phase of the relationship between
          the Parties described in this Agreement, which covers exclusive use by
          FFF and its agents of Omrigam NF in Clinical Trials and exclusive
          distribution by FFF of Omrigam NF under a Treatment Protocol,
          providing a Treatment Protocol is approved by the FDA.

     1.16. "INVESTIGATOR" - means an individual who actually conducts a clinical
          investigation (i.e., under whose immediate direction the drug is
          administered or dispensed to a subject), as defined in 21 CFR Section
          312.3. In a team of investigators, the Investigator is the leader of
          the team. A licensed practitioner who receives and dispenses the
          Investigational Drug under a Treatment Protocol is an Investigator, in
          accordance with 21 CFR Section 312.35(a)(3).

     1.17. "MANUFACTURING SPECIFICATIONS" - means the specifications in the
          Omrix IND, as amended from time to time, for compliance with cGMP
          standards and specifications for the chemistry, manufacturing and
          quality control, labeling, packaging and shipping of the
          Investigational Drug.

     1.18. "OMRIX IND" - means the Investigational New Drug Application
          submitted to the FDA by Omrix in 2001 and held by Omrix for Omrigam
          NF, until amended in December 2005 -- the amended IND is the FFF IND.

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL      Page 2 of 27

<PAGE>

     1.19. "OMRIGAM NF" - means Omrix's proprietary polyvalent IGIV.

     1.20. "OMRIX TECHNOLOGY" - means all the technical information, whether
          tangible or intangible, including (without limitation) any and all
          data, techniques, discoveries, inventions, processes, formulations,
          know-how, patents (including any divisional, continuation, extension,
          reissue, reexamination certificate, or renewal patents), patent
          applications, inventor certificates, trade secrets, method of
          production and other proprietary information, that Omrix has rights to
          (as either owner, licensee or sublicense), or may hereafter obtain
          rights to, relating to Omrigam NF.

     1.21. "PHASE 2 CLINICAL TRIAL" - means a Phase 2 clinical trial conducted
          by FFF or its agents in which the safety and efficacy of the
          Investigational Drug are evaluated in up to five (5) human patients
          with primary immune deficiency for the purpose of obtaining approval
          from the FDA of a Biologics License Application and a Treatment
          Protocol.

     1.22. "PHASE 3 CLINICAL TRIAL" - means a Phase 3 clinical trial conducted
          by FFF or its agents in which the safety and efficacy of the
          Investigational Drug are evaluated in up to fifty (50) human patients
          with primary immune deficiency for the purpose of obtaining approval
          from the FDA of a Biologics License Application and a Treatment
          Protocol.

     1.23. "REGULATORY FILINGS" - means any document required under the US
          Federal Food, Drug and Cosmetics Act and associated regulations in
          Title 21 of the CFR.

     1.24. "SPONSOR" - means the same as in 21 CFR Section 312.3 and refers to
          the entity that holds the IND for the investigational drug. The
          Sponsor is responsible for compliance with all sponsor
          responsibilities set forth in 21 CFR Part 312. FFF is the Sponsor of
          the FFF IND, as defined in Section 1.10, above.

     1.25. "TAXES" - means all taxes associated with the distribution, sale and
          delivery of Omrigam NF, including but not limited to sales, use,
          excise, withholding, value-added and similar taxes and all customs,
          duties or other governmental impositions, but excluding taxes
          calculated on Omrix's net income.

     1.26. "TREATMENT PROTOCOL" - under this Agreement means a treatment
          protocol ("TREATMENT PROTOCOL"), as described in 21 CFR Section
          312.35(a), that will be submitted by FFF under the FFF IND to use the
          Investigational Drug to treat US patients with primary immune
          deficiency and other immune diseases who are not enrolled as subjects
          in the Clinical Trials. The FDA may approve a Treatment Protocol as
          early as during a Phase 2 clinical trial (21 CFR Section 312.34(a)).
          Under a Treatment Protocol, the Investigational Drug may be
          distributed to a specified group of physicians, who function as
          Investigators, and who may provide the Investigational Drug to
          patients in accordance with applicable informed consent (21 CFR Part
          50) and Institutional Review Board (21 CFR Part 56) requirements. In
          contrast to use in the Clinical Trials, the Parties may charge for the
          use of the Investigational Drug under a Treatment Protocol under
          conditions specified in 21 CFR Section 312.7(d)(2).

     1.27. "TREATMENT PROTOCOL CHARGE PRICE" - means the price authorizedby the
          FDA under 21 CFR Section 312.7(d)(2) to charge patients or their
          insurance for the Investigational Drug provided to patients under the
          Treatment Protocol.

     1.28. "TREATMENT PROTOCOL PURCHASE PRICE" - means the price FFF shall pay
          Omrix for the Investigational Drug that will be provided to patients
          under the Treatment Protocol.

2.   INVESTIGATIONAL DRUG

     2.1. Omrigam NF. The Investigational Drug under this Agreement is Omrigam
          NF, which may be used in the US only in the Clinical Trials and under
          a Treatment Protocol, prior to approval by

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL      Page 3 of 27

<PAGE>

          the FDA of a Biologics License Application. Omrix is and remains under
          this Agreement the exclusive owner of Omrigam NF.

     2.2. Regulatory Status. The Investigational Drug is a biologic for which a
          BLA has not yet been submitted to the FDA to obtain approval to market
          the product in the US. FFF will be the sponsor of an amended IND for
          the Investigational Drug (i.e., the FFF IND). The Parties' intent
          under this Agreement is for FFF to use data collected in the Clinical
          Trials to prepare a BLA that Omrix will submit to the FDA for approval
          to market Omrigam NF in the US in the Commercial Phase, as defined in
          section 1.5, above, and in accordance with section 3, below.

     2.3. Quality Standards and Rejections.

          a.   Quality Standards. Omrix shall be responsible for supplying all
               Investigational Drug used under this Agreement in compliance with
               cGMP standards, the specifications in the Omrix IND for the
               chemistry, manufacturing and quality control and all applicable
               FDA requirements set forth in 21 CFR Part 312 for labeling,
               packaging and shipping of investigational drugs (hereafter
               collectively "MANUFACTURING SPECIFICATIONS").

          b.   Change in Manufacturing Specifications. Omrix will advise FFF in
               writing of any proposed modifications to the Manufacturing
               Specifications prior to implementation. Omrix will only implement
               the modified Manufacturing Specifications after submitting to the
               FDA (through FFF) an information amendment to supplement the IND,
               if necessary under 21 CFR 312.23.

          c.   Rejections. FFF shall have the right to return to Omrix any
               Investigational Drug FFF that upon receipt from Omrix does not
               comply with Omrix's Manufacturing Specifications. FFF shall have
               ten (10) calendar days ("Inspection Period") from receipt of a
               shipment to perform a visual inspection for damage to the
               packaging or immediate container and to reject any damaged
               Investigational Drug in the shipment. FFF must send a written
               rejection notice to Omrix within the ten (10) day Inspection
               Period and must detail the basis for the rejection. FFF shall
               return any damaged units of Investigational Drug to Omrix. Omrix
               shall replace any rejected and returned damaged units of
               Investigational Drug without cost to FFF providing that the
               damage was not sustained after receipt of the Investigational
               Drug by FFF. If FFF does not deliver written notice to Omrix
               within the applicable Inspection Period of receipt of a shipment
               that FFF rejects such shipment because of non-compliance, FFF
               will be deemed to have accepted the shipment. If after an inquiry
               by Omrix it will be determined that any rejection was made in
               error, FFF will bear all costs associated with making such
               determination and will immediately pay Omrix the above cost
               together with any unpaid sum relating to the alleged
               non-complying Investigational Drug, and any other cost incurred
               by Omrix in connection with the alleged non-compliance.

     2.4. Investigational Use. The Investigational Drug may be used under this
          Agreement in the US only in the Clinical Trials and under a Treatment
          Protocol, in compliance with all applicable FDA regulations and
          approvals and in accordance with this Agreement.

     2.5. Supply and Purchase Commitments.

          a.   Omrix shall supply all Investigational Drug necessary for timely
               completion of the Clinical Trials and as needed to meet demand
               under the Treatment Protocol, subject to the supply of recovered
               plasma volume provided to Omrix under the DCI Contract.

          b.   Omrix agrees to sell to FFF and FFF shall purchase all
               Investigational Drug produced by Omrix from recovered plasma
               purchased pursuant to the DCI Contract provided, however, that
               under no circumstances shall FFF be responsible for purchasing
               more than *** of the Investigational Drug in any calendar year
               unless Omrix has obtained prior written approval of FFF to
               purchase such additional

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL      Page 4 of 27

<PAGE>

               amounts. Notwithstanding the foregoing, during any partial
               calendar year under this Agreement, the number of grams of
               Investigational Drug which FFF shall be required to purchase
               shall be a pro rata amount based on the actual number of days
               during such calendar year in which this Agreement is in force and
               during which the Treatment Protocol is approved and effective.

          c.   Omrix shall assure that the Investigational Drug is shipped with
               the statement, "Caution: New Drug - Limited by United States law
               to investigational use," on the package label as required by 21
               CFR Section 312.6.

     2.6. Exclusive Distributor. FFF shall be the exclusive distributor of the
          Investigational Drug in the US.

     2.7. Handling Specifications. FFF shall be responsible for assuring that
          the Investigational Drug is handled by FFF, Investigators, and FFF's
          agents and subcontractors according to Omrix's specifications set
          forth in the FFF IND for the handling, storage, use, transport and
          general possession of Omrigam NF ("HANDLING SPECIFICATIONS"). FFF
          shall be responsible for maintaining accurate and current records
          regarding handling, storage and transport of the Investigational Drug
          for review by Omrix and the FDA or other regulatory agencies.

     2.8. Unused Investigational Drug. All unused quantities of Investigational
          Drug that have been provided to FFF under this Agreement for use in
          the Clinical Trials shall be destroyed by FFF, or, at Omrix's option,
          returned to Omrix, at Omrix's cost, upon any of the following events:
          i) the conclusion or termination of the Clinical Trials; ii) the IND
          or Treatment Protocol is placed on clinical hold by the FDA under 21
          CFR Section 312.34(d) and Section 312.42 for in excess of six (6)
          months unless otherwise agreed by the Parties; iii) upon approval of a
          BLA for Omrigam NF; or iv) upon termination of this Agreement. FFF
          shall be responsible for assuring that Investigators return all unused
          Investigational Drug to FFF for destruction or return to Omrix, as
          applicable.

     2.9. DCI Contract. The Parties recognize that Omrix has entered into a
          5-year supply agreement with DCI (the "DCI Contract") that is
          necessary for Omrix to provide Investigational Drug to FFF for use
          under this Agreement. If this Agreement is terminated under Sections
          15.2.b, 15.2.c, 15.3.a, 15.3.c or 15.3.d, then the Parties agree to
          share equally any loss incurred or profit realized by Omrix under the
          DCI Contract, provided, however, that FFF shall not be responsible for
          any loss based on DCI providing Omrix with more than *** liters of
          recovered plasma per calendar year unless Omrix has obtained FFF's
          prior written agreement that FFF will bear responsibility for such
          loss. If this Agreement is so terminated as set forth in the previous
          sentence, Omrix will make commercially reasonable efforts to resell
          such plasma and FFF agrees to be responsible to Omrix for an amount
          equal to *** of the difference, if any, that the price Omrix pays for
          such plasma is greater than the price that Omrix receives upon a
          resale of such plasma *** and Omrix agrees to pay FFF an amount equal
          to *** of the difference, if any, that the price Omrix pays for such
          plasma is less than the price that Omrix receives upon a resale of
          such plasma ***. Accordingly, FFF shall pay to Omrix fifty percent
          (50%) of the amount due by Omrix under the DCI Contract at least five
          (5) business days prior to the date that Omrix is due to pay such
          amounts to DCI, and Omrix shall reimburse FFF such amount, less the
          *** (or plus ***),if any, upon receipt of payment by a third party
          for the plasma. For the purposes of this Section 2.9, the amount that
          Omrix receives upon a resale shall be calculated net of all taxes,
          shipping and other associated out of pocket expenses incurred by
          Omrix in the resale of the plasma. Alternatively, if Omrix assigns
          the DCI Contract, or agrees with DCI on a termination fee, or enters
          into any other arrangement for disposal of the DCI Contract, then FFF
          agrees to reimburse Omrix for *** of any cost or loss incurred by
          Omrix resulting from entering into any such arrangement, provided
          that such arrangement has been approved by FFF in advance and Omrix
          agrees to pay FFF *** of any profit realized by Omrix resultin from
          entering into any such arrangement. In addition, if this Agreement is
          terminated by Omrix under Section 15.2.a or 15.2.d, or by FFF under
          Section 15.3.e, FFF shall

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL      Page 5 of 27

<PAGE>

          be responsible for all amounts committed by Omrix in connection with
          the DCI Contract; provided, however, that if Omrix requires FFF to
          bear such costs in connection with such contract, FFF will have the
          option to have the DCI Contract assigned to FFF, subject to the
          approval of DCI, and Omrix shall have no obligations or liability
          after such assignment. This Section 2.9 shall survive termination of
          this Agreement. If Omrix enters into any other long term supply
          agreements for recovered plasma during the Term, which are approved by
          FFF in writing, then each party's responsibilities under such
          agreements will be treated in the same manner as described in this
          Section regarding the DCI Contract.

     2.10. Payments to Fund Expansion. FFF shall pay to Omrix non-refundable
          payments aggregating to ***, which Omrix will apply to expansion of
          Omrix's capacity to manufacture Omrigam NF. Notwithstanding the
          foregoing, Omrix will refund this amount to FFF only if the Agreement
          is terminated under Section 15.2.b or 15.3.e (as regards the Treatment
          Protocol Charge Price), to the extent such amount has not been
          expended on such expansion. These payments will be made in six (6)
          equal monthly installments of *** each. In the event the FDA approves
          the use of the Investigational Drug in the Treatment Protocol for the
          primary immune deficiency, ITP, CLL. BMT, pediatric HIV and Kawasaki's
          Disease disease states, the first payment will commence ninety (90)
          days after the Treatment Protocol is approved by the FDA. In the event
          the FDA approves the use of the Investigational Drug in the Treatment
          Protocol for the foregoing six (6) disease states and also for the
          CIDP, GBS and Myasthenia Gravis neurological disorders, then the first
          payment will instead commence thirty (30) days after the Treatment
          Protocol is approved by the FDA.

3.   COMMERCIAL PHASE

     3.1. Post-FDA Approval. The Commercial Phase means the phase of the
          relationship between the Parties after FDA approval of a Biologics
          License Application has been obtained and Omrigam NF may be marketed
          in the US.

     3.2. Exclusive Distributor. The terms and conditions between the Parties
          for the Commercial Phase are set forth in the agreement, SUPPLY AND
          DISTRIBUTION AGREEMENT: COMMERCIAL PHASE ("COMMERCIAL PHASE
          AGREEMENT"), attached hereto as Exhibit A. Under the Commercial Phase
          Agreement, FFF shall be the exclusive distributor of Omrigam NF in the
          US.

     3.3. Commercial Phase Agreement. Execution of the Commercial Phase
          Agreement is a concurrent condition of execution of this Agreement.

4.   CLINICAL TRIALS

     4.1. General Responsibilities.

          a.   FFF. FFF will be the sponsor of the Clinical Trials under the FFF
               IND, as defined in section 1.10, above. FFF shall be responsible,
               at its own cost, for conducting the Clinical Trials through a
               qualified Contract Research Organization (CRO). FFF will be the
               exclusive contact with the FDA on all matters related to the FFF
               IND, the Clinical Trials and the Treatment Protocol. FFF shall
               use its best reasonable efforts to conduct the Clinical Trials in
               a timely manner and in accordance with this Agreement, the
               approved protocol for the individual Clinical Trial and all
               applicable federal, state and local regulatory requirements. FFF
               shall keep Omrix informed in a timely manner of all regulatory
               issues, the conduct of the Clinical Trials and use of the
               Investigational Drug under the Treatment Protocol and will obtain
               Omrix's approval prior to all regulatory decisions.

          b.   Omrix. Omrix shall use its best reasonable efforts to work
               collaboratively and in a timely manner with FFF in meeting all
               regulatory requirements related to the FFF IND, including

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL      Page 6 of 27

<PAGE>

               without limitation providing information requested by FFF for use
               in correspondence with the FDA related to the Clinical Trials.

     4.2. FFF Responsibilities.

          a.   Sponsor's Obligations. FFF shall be responsible for assuring that
               all Sponsor obligations under 21 CFR Part 312 are met either by
               FFF or as delegated by FFF to the CRO.

          b.   Contract Research Organization. FFF shall be responsible for
               selecting and hiring a CRO to conduct the Clinical Trials, within
               thirty (30) days of notice from the FDA of approval of the FFF
               IND. FFF shall be responsible for overseeing and paying the CRO
               to conduct the Clinical Trials.

          c.   Clinical Trials. FFF shall contract with the CRO to conduct the
               following Clinical Trials:

               1.   Phase 2 Clinical Trial. Immediately upon hiring the CRO and
                    obtaining all necessary regulatory approvals from the FDA
                    and the IRB, the CRO shall initiate a Phase 2 Clinical Trial
                    with qualified Investigators in which the safety and
                    efficacy of the Investigational Drug will be evaluated in
                    five (5) or fewer patients with primary immune deficiency.
                    FFF and Omrix shall work closely with the CRO in preparing
                    detailed protocols for the Phase 2 Clinical Trial as needed
                    to obtain FDA clearance.

               2.   Phase 3 Clinical Trial. Upon conclusion of the Phase 2
                    Clinical Trial and obtaining all necessary regulatory
                    approvals from the FDA and the IRB, the CRO shall initiate a
                    Phase 3 Clinical Trial with qualified Investigators in which
                    the safety and efficacy of the Investigational Drug will be
                    evaluated in fifty (50) or fewer patients with primary
                    immune deficiency. FFF and Omrix shall work closely with the
                    CRO in preparing detailed protocols for the Phase 3 Clinical
                    Trial as needed to obtain FDA clearance.

          d.   Protection of Human Subjects. FFF shall be responsible for
               assuring that the Clinical Trials are conducted in compliance
               with all applicable FDA regulations protecting human subjects as
               set forth in 21 CFR Parts 50 and 56. FFF shall assure that no
               subject will receive the Investigational Drug until the
               Investigator's IRB has obtained IRB approval of the Clinical
               Trial protocol and informed consent form, the subject has been
               fully informed of the risks and benefits of participating in the
               Clinical Trial and the subject has signed the approved informed
               consent form.

          e.   Regulatory Compliance. FFF shall be responsible for assuring that
               the Clinical Trials are conducted in compliance with all
               applicable FDA regulations, including without limitation the
               following:

               1.   Compliance with Good Clinical Practices ("GCPS"), prudent
                    research practices and the IRB-approved protocol for the
                    individual Clinical Trial.

               2.   Compliance with the Health Insurance Portability and
                    Accountability Act of 1996, as codified at 42 USC Section
                    1320d ("HIPAA") and its implementing regulations, including
                    without limitation 45 CFR Parts 160 and 164 ("the Privacy
                    Regulations") and 45 CFR Parts 142 (the "Security
                    Regulations"), collectively the "HIPAA REQUIREMENTS." FFF
                    shall assure compliance with applicable HIPAA Requirements
                    for obtaining and disclosing protected health information
                    ("PHI"), as that term is defined in 45 CFR Section 164.501,
                    in the Clinical Trials.

               3.   The CRO shall not retain, employ or involve any person in
                    conducting the Clinical Trials if such person is (i)
                    debarred by the FDA under 21 USC 335a; (ii) the subject of a
                    disqualification proceeding or is disqualified as a clinical
                    investigator pursuant to 21 CFR.

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL      Page 7 of 27

<PAGE>

                    Section 312.70; or (iii) has been excluded from
                    participation in any federal health care program pursuant to
                    Title XI of the Social Security Act.

               4.   FFF shall be responsible for obtaining from all
                    Investigators information regarding financial interests as
                    necessary for Omrix to comply with any disclosure
                    requirements to the FDA under 21 CFR Part 54.

          f.   Investigator's Brochure. FFF shall be responsible for assuring
               that all Investigators receive a copy of the Investigator's
               Brochure as required under 21 CFR Section 312.55(a).

          g.   Safety Information. FFF shall be responsible for assuring that
               safety information regarding life-threatening, serious and/or
               unexpected adverse drug experiences is collected during the
               Clinical Trials as required under 21 CFR Section 312.32 and in
               accordance with FDA guidance published November 30, 2005. FFF
               shall promptly provide to Omrix written reports of any and all
               such adverse drug experiences for Omrix's review and evaluation.
               FFF shall notify Omrix immediately by telephone of any unexpected
               or life-threatening adverse event associated with use of the
               Investigational Drug. FFF shall be responsible for investigating
               all safety information it receives and following-up as
               appropriate under 21 CFR Section 312.32(d). FFF shall be
               responsible for preparing and submitting written IND safety
               reports as required under 21 CFR Section 312.32(c) on all serious
               and unexpected adverse drug experiences to the FDA as soon as
               possible but not later than fifteen (15) calendar days of
               receiving notice of such experiences. FFF shall be responsible
               for notifying the FDA of any unexpected fatal or life-threatening
               drug experience by telephone or facsimile as soon as possible but
               not later than seven (7) calendar days of receiving information
               about such experiences.

          h.   Distribution and Disposition Investigational Drug. FFF shall be
               responsible for assuring that the Investigational Drug is
               distributed only to qualified Investigators for use in the
               Clinical Trials in accordance with the approved protocol. FFF
               shall assure that any and all unused quantities of the
               Investigational Drug dispensed to Investigators for use in the
               Clinical Trials are returned by Investigators to FFF and disposed
               of by FFF in accordance with section 2.8, above. FFF shall
               maintain complete, accurate and current records of the
               disposition of all Investigational Drug as required under 21 CFR
               Section 312.59 and provide such records to Omrix at the
               conclusion of the Clinical Trials.

          i.   IND Information. FFF shall provide to Omrix the complete FFF IND
               and copies of any amendments to the IND at least twenty-four (24)
               hours prior to submission to the FDA.

          j.   Maintain FFF IND. FFF shall be responsible for complying with all
               regulatory requirements necessary to maintain the FFF IND and
               providing the FDA with any supplemental information to amend the
               IND as required under 21 CFR Section 312.31.

          k.   Reports and Records. FFF shall be primarily responsible for
               preparing all FDA required reports and records in consultation
               with Omrix. FFF shall submit all required reports to the FDA. FFF
               shall maintain all FDA required records for two (2) years after
               approval of the BLA as required under 21 CFR Section 312.57(c) or
               two (2) years after termination of this Agreement, whichever
               occurs earlier.

     4.3. Omrix Responsibilities.

          a.   Supply Investigational Drug. Omrix shall supply to FFF all
               Investigational Drug necessary for the Clinical Trials at its
               expense and free of charge, subject to volumes of recovered
               plasma provided to Omrix under the DCI Contract. Omrix shall
               provide the Investigational Drug in compliance with all
               applicable FDA requirements for labeling, packaging and shipping
               of investigational drugs set forth in 21 CFR Part 312. Such
               packaging shall include all materials needed to infuse the
               Investigational Drug or placebo.

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL      Page 8 of 27

<PAGE>

          b.   Maintenance of FFF IND. Omrix shall cooperate with FFF in
               complying with all regulatory requirements necessary to maintain
               the FFF IND as far as such requirements relate to the
               manufacturing, labeling and shipping of the Investigational Drug
               and providing FFF with any supplemental information needed to
               amend the IND as required under 21 CFR Section 312.31.

          c.   Records. FFF and Omrix shall maintain adequate records of
               shipments of Investigational Drug, as required under 21 CFR
               Section 312.57(a) including the recipient, date, quantity, and
               batch or code mark of each shipment.

          d.   Safety Information. Omrix shall review and evaluate all safety
               information received from FFF and provide timely feedback to FFF
               to allow FFF to comply with its safety reporting obligations as
               described in section 4.2.g, above. Omrix shall cooperate with FFF
               in investigating all serious adverse events associated with use
               of the Investigational Drug, as required under 21 CFR Section
               312.32(d).

          e.   Reports. Omrix shall cooperate with FFF as needed to prepare all
               reports required by the FDA to assure timely submission of
               complete and accurate reports.

     4.4. Data. FFF shall own all data generated in the Clinical Trials. The
          Parties shall consult with each other in the interpretation of the
          data. FFF shall maintain the data as needed to prepare reports and
          maintain records required under 21 CFR Part 312 and Omrix will use the
          data to prepare the BLA. FFF shall provide Omrix with copies of all
          data generated in the Clinical Trials on a regular basis, and, in any
          case, no less frequently than quarterly. Upon termination of this
          Agreement, Omrix shall cease to use all data provided to Omrix by FFF
          pursuant to this section 4.4 unless FFF agrees otherwise in writing or
          until the transfer of the data from FFF to Omrix in accordance with
          section 15.4 of this Agreement.

5.   TREATMENT PROTOCOL

     5.1. FFF Responsibilities.

          a.   Treatment Protocol. FFF shall be responsible for obtaining a
               Treatment Protocol, as defined in section 1.26, under the FFF IND
               and in accordance with the provisions of this section 5.1.

               1.   Treatment Protocol. FFF shall prepare a treatment protocol
                    ("Treatment Protocol") in consultation with and information
                    provided by Omrix and in accordance with 21 CFR Section
                    312.35(a) to use the Investigational Drug to treat patients
                    with primary immune deficiency who are not enrolled as
                    subjects in the Clinical Trials. FFF has been engaged in
                    discussions with the FDA regarding the Treatment Protocol
                    and shall continue to be responsible for negotiating the
                    terms of the Treatment Protocol with the FDA. FFF shall
                    prepare the Treatment Protocol in time for FFF to submit it
                    to the FDA immediately after initiation of the Phase 2
                    Clinical Trial with the goal of obtaining approval during or
                    immediately after the conclusion of the Phase 2 Clinical
                    Trial. FFF shall be the sponsor of the Treatment Protocol
                    and shall submit the Treatment Protocol to the FDA under the
                    FFF IND. In addition, FFF will provide Omrix with an
                    electronic copy of the packaging material which will be used
                    in the Treatment Protocol consistent with all FDA
                    requirements.

               2.   Approval of the Treatment Protocol. The Treatment Protocol
                    shall be deemed approved thirty (30) days after the date the
                    FDA receives the Treatment Protocol unless the FDA either:
                    (a) provides earlier notification that treatment use of the
                    Investigational Drug may begin or (b) places the Treatment
                    Protocol on clinical hold under 21 CFR Section 312.34(d). If
                    no communication has been received from the FDA within forty
                    (40) days of submission of the Treatment Protocol, Omrix and
                    FFF shall confirm with the FDA that treatment use of the
                    Investigational Drug may begin.

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL      Page 9 of 27

<PAGE>

          b.   Contract Research Organization. FFF shall be responsible for
               selecting and hiring a CRO or equivalent within thirty (30) days
               of approval of the Treatment Protocol, as defined in Section
               5.1.a.2, above, to implement the Treatment Protocol, including
               without limitation selecting qualified physicians as
               Investigators, obtaining approval as needed by local IRBs,
               assuring patients who receive the Investigational Drug have been
               fully informed of the risks and benefits and have signed an IRB
               approved informed consent form.

          c.   Distribution and Disposition of Investigational Drug. FFF shall
               be the exclusive distributor of the Investigational Drug under
               the Treatment Protocol. FFF shall assure that the Investigational
               Drug is distributed in compliance with all applicable regulatory
               requirements set forth in 21 CFR Section 312.34 and Section
               312.35. FFF shall assure that any and all unused quantities of
               the Investigational Drug dispensed under the Treatment Protocol
               shall be returned by Investigators to FFF and disposed of by FFF
               in accordance with section 2.8, above. FFF shall be responsible
               for maintaining complete and accurate records of the disposition
               of the Investigational Drug as required under 21 CFR Section
               312.59.

          d.   Regulatory Compliance. FFF shall be responsible for assuring that
               the Investigational Drug is distributed in compliance with all
               applicable regulatory requirements generally related to INDs and
               specifically those related to Treatment Studies set forth in 21
               CFR Section 312.34 and Section 312.35, including without
               limitation the following:

               1.   Investigators. Licensed practitioners who receive the
                    Investigational Drug under the Treatment Protocol are
                    Investigators under 21 CFR Section 312.35(a)(3).
                    Investigators who administer the Investigational Drug under
                    the Treatment Protocol shall be referred to hereafter as
                    "TREATMENT PROTOCOL INVESTIGATORS." FFF shall assure that
                    all Treatment Protocol Investigators comply with all
                    applicable requirements for "investigators" under 21 CFR
                    Part 312, sign FDA Form-1572 and provide information
                    regarding financial interests in compliance with 21 CFR Part
                    54.

               2.   Human Subject Protections. FFF shall be responsible for
                    assuring that the Investigational Drug is administered by
                    Investigators in compliance with all applicable requirements
                    for informed consent under 21 CFR Part 50 and IRBs under 21
                    CFR Part 56.

               3.   Safety Reports. FFF shall be responsible for assuring that
                    safety information is collected from Investigators
                    participating in the Treatment Protocol as required under 21
                    CFR 312.34 and shall promptly provide such information to
                    Omrix. FFF shall treat safety information collected under
                    the Treatment Protocol, as described in Section 4.2.g.,
                    above.

          e.   Monitor Effects. FFF shall be responsible for assuring that
               information about the safety and effectiveness of the
               Investigational Drug is collected from the Treatment Protocol
               Investigators as required under 21 CFR Section 312.35(a)(1)(v).

          f.   Reports and Records. FFF shall be primarily responsible for
               preparing reports of safety and effectiveness of the
               Investigational Drug used under the Treatment Protocol and
               providing such reports to Omrix in a timely manner. FFF shall
               maintain all records for two (2) years after approval of the BLA
               or two (2) years after termination of this Agreement, whichever
               occurs earlier.

     5.2. Omrix's Rights and Responsibilities.

          a.   Treatment Protocol. Omrix shall provide to FFF in a timely manner
               any information in Omrix's possession about the Investigational
               Drug that is necessary for FFF to prepare the Treatment Protocol,
               including without limitation technical, pre-clinical, clinical,
               and

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL     Page 10 of 27

<PAGE>

               information regarding the Manufacturing Specifications. Omrix
               shall provide FFF with feedback in a timely manner on drafts of
               the Treatment Protocol.

          b.   Investigational Drug. Omrix shall provide to FFF all
               Investigational Drug needed for the Treatment Protocol in
               accordance with sections 2, above and 5.4, below.

          c.   General Responsibilities. Omrix shall be responsible for meeting
               the obligations of Omrix set forth in Sections 4.3. (b)-(e),
               above as they relate to use of the Investigational Drug under the
               Treatment Protocol

     5.3. Data. FFF shall own all data regarding the effect of the
          Investigational Drug provided under the Treatment Protocol. The
          Parties shall consult with each other in the interpretation of the
          data. FFF shall keep copies of all data as needed to prepare reports
          and maintain records required under 21 CFR Part 312 and to prepare the
          BLA. FFF shall provide Omrix with copies of all data regarding the
          effect of the Investigational Drug under the Treatment Protocol on a
          regular basis, and, in any case, no less frequently than quarterly.
          Upon termination of this Agreement, Omrix shall cease to use all data
          provided to Omrix by FFF pursuant to this section 5.3 unless FFF
          agrees otherwise in writing or until the transfer of the data from FFF
          to Omrix in accordance with section 15.4 of this Agreement.

     5.4. Purchase of Investigational Drug.

          a.   Purchase Price of Investigational Drug. FFF shall purchase the
               Investigational Drug from Omrix for distribution under the
               Treatment Protocol at the price specified in the Treatment
               Protocol Pricing Sheet, attached hereto as Exhibit C. This
               purchase price shall be referred to hereafter in this Agreement
               as the "TREATMENT PROTOCOL PURCHASE PRICE." The Treatment
               Protocol Purchase Price shall be *** per gram, and shall be
               subject to an upward price adjustment based on changes in the
               cost of plasma under the DCI Contract The price adjustment will
               be equal to *** of the change in the price under the DCI
               Contract. For example, if the price per liter for recovered
               plasma increases by *** per liter, then the corresponding
               increase in the Treatment Protocol Purchase Price will be ***
               per gram.

          b.   Charge Price of Investigational Drug.

               1.   FDA Price Limitations. The Parties acknowledge that under 21
                    CFR Section 312.7(d)(2) FFF may charge patients or their
                    insurance for use of the Investigational Drug used under the
                    Treatment Protocol. However, the FDA limits the price that
                    may be charged to reimbursement of costs related to the
                    manufacture, research, development and handling of the
                    Investigational Drug (21 CFR Section 312.7(d)(3)).

               2.   Treatment Protocol Charge Price. FFF and Omrix shall
                    collaboratively determine a price structure to charge
                    patients or their insurance for the Investigational Drug
                    provided under the Treatment Protocol that complies with 21
                    CFR Section 312.7(d)(3). This price shall be referred to
                    hereafter in this Agreement as the "TREATMENT PROTOCOL
                    CHARGE PRICE." The formulation of the Treatment Protocol
                    Charge Price is provided in the TREATMENT PROTOCOL PRICING
                    SHEET, attached hereto as Exhibit C. The Treatment Protocol
                    Charge Price shall consist of the Treatment Protocol
                    Purchase Price, as described above and a COST RECOVERY
                    AMOUNT. The Cost Recovery Amount that will be the sum of
                    itemized costs related to manufacturing the Investigational
                    Drug, conducting the Clinical Trials and distributing the
                    Investigational Drug under the Treatment Protocol. The
                    itemized costs and calculation of the Cost Recovery Amount
                    are set out in the Treatment Protocol Pricing Sheet. The
                    Treatment Protocol Charge Price must be authorized by FDA.

               3.   FDA Authorization of Charge Price. FFF shall prepare and
                    submit to the FDA a written notification of the proposed
                    Treatment Protocol Charge Price as required under 21 CFR

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL     Page 11 of 27

<PAGE>

                    Section 312.(d)(2). The Treatment Protocol Charge Price is
                    deemed authorized by the FDA and may be put into effect
                    thirty (30) days after the FDA receives the notification,
                    unless the FDA notifies FFF to the contrary. FFF shall keep
                    Omrix informed in a timely manner of all communications with
                    the FDA regarding authorization of the Treatment Protocol
                    Charge Price.

          c.   Purchase by FFF of Investigational Drug.

               1.   Promotion and Advertising. The Parties acknowledge that FDA
                    regulations prohibit commercial promotion or advertising of
                    the Investigational Drug used under the Treatment Protocol
                    (21 CFR Section 312.7(d)(2)). Any informational material
                    used in connection with the Treatment Protocol must be
                    approved by Omrix.

               2.   Orders. FFF shall submit quarterly written purchase orders
                    to Omrix for the Investigational Drug to be used under the
                    Treatment Protocol. The amount of FFF's purchase orders
                    shall be based on the quantity of Investigational Drug
                    manufactured by Omrix using recovered plasma obtained under
                    the DCI Contract but shall be subject to the limitations set
                    forth in section 2.5, above. All signed purchase orders must
                    be faxed to Omrix at +972-3-535-0265. Purchase orders shall
                    be signed by an authorized official of FFF and shall
                    specify: (a) the purchase order number; (b) quantities; (c)
                    Treatment Protocol Purchase Price; (d) requested delivery
                    schedule; (e) preferred shipping method; (f) exact "Ship to"
                    address; and (g) any other relevant detail. All purchase
                    orders shall be binding on the Parties only after FFF has
                    received written confirmation of the order from Omrix. Omrix
                    reserves the right to cancel, suspend, refuse, or delay any
                    orders if FFF fails to make payment when due as required in
                    Section 5.4.c.4, below or otherwise fails to comply with the
                    terms and conditions of this Agreement.

               3.   Forecasts; Delivery. During the Term of this Agreement,
                    Omrix shall, by November 30th of each calendar year, provide
                    FFF with a non-binding good faith forecast for the following
                    calendar year, broken down into months, for the quantity of
                    the Investigational Drug that Omrix anticipates producing
                    under the DCI Contract. The forecast will be updated every
                    other month, or more frequently, as determined by Omrix. The
                    Parties acknowledge that the actual supply of the
                    Investigational Drug that Omrix is obligated to provide is
                    subject to volumes provided under the DCI Contract. Omrix
                    shall ship the quantity of Investigational Drug ordered, in
                    accordance with the shipping dates set forth in the
                    forecasts. Omrix shall be responsible for payment of the
                    costs of shipping and insurance associated with the delivery
                    the Investigational Drug. Delivery will be FOB at FFF's
                    designated facility in the United States or at any
                    alternative receiving location if agreed in writing by the
                    Parties. Risk of loss in the Investigational Drug shall pass
                    to FFF at the time the Investigational Drug is received by
                    FFF.

               4.   Invoices. Omrix shall invoice FFF upon shipment (i.e., when
                    shipped from Omrix's plant) for the Treatment Protocol
                    Purchase Price for all shipped Investigational Drug. The
                    terms for all invoices shall be net 60 calendar days from
                    the invoice date, unless paid within 30 calendar days, which
                    30-day payments will receive a 2% discount. If FFF disagrees
                    for any reason with the amount of an invoice submitted by
                    Omrix, FFF shall notify Omrix in writing of such
                    disagreement within fifteen (15) calendar days of receipt of
                    such invoice and the Parties shall promptly attempt to
                    resolve the difference.

               5.   Payments. FFF shall pay Omrix the Treatment Protocol
                    Purchase Price in US dollars for all received
                    Investigational Drug that is not rejected by FFF under
                    section 2.3.c, above. Payments not received by Omrix when
                    due are subject to a late payment charge at the lower of:
                    (i) one and one half percent (1.5%) per month; (ii) the
                    maximum interest permitted under applicable law. Payments
                    are exclusive of all shipping and distribution costs and
                    Taxes, which shall be borne by FFF. FFF shall pay all Taxes
                    associated with the sale and delivery of all Investigational
                    Drug. All payments to Omrix hereunder

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL     Page 12 of 27

<PAGE>

                    represent net amounts to be received by Omrix. If any Taxes
                    are found to be applicable to such payments to Omrix and/or
                    if FFF shall be required to deduct, collect, withhold or pay
                    such Taxes, the sum payable to Omrix shall be increased as
                    may be necessary so that after making all required
                    deductions, Omrix receives the amount equal to the sum it
                    would have received had no such deductions been made.

6.   BIOLOGICS LICENSE APPLICATION

     6.1. FFF Responsibilities.

          a.   Preparation of BLA. FFF shall be primarily responsible for
               preparing a clinical study report for the BLA demonstrating the
               safety, purity and potency of Omrigam NF in patients with primary
               immune deficiency, in accordance with 21 CFR Section 601.2
               (hereafter, the "OMRIGAM NF BLA"). FFF shall consult extensively
               with Omrix in preparing drafts for review and comment by Omrix
               and shall obtain from Omrix written approval of a final report
               for Omrix to submit to the FDA. FFF shall aim to complete the
               clinical study report as soon as sufficient data are available
               from the Clinical Trials and the Treatment Protocol to meet FDA
               requirements.

          b.   Costs. FFF shall be responsible for paying all fees and costs
               associated with preparing and submitting the Omrigam NF BLA to
               the FDA.

     6.2. Omrix Rights and Responsibilities.

          a.   Information. Omrix shall provide to FFF in a timely manner all
               relevant and material information in Omrix's possession needed by
               FFF to prepare the Omrigam NF BLA in accordance with 21 CFR
               Section 601.2, including without limitation: data from
               pre-clinical and clinical studies and statements of compliance
               with 21 CFR Parts 50, 54 and 56 for all clinical studies.

          b.   Regulatory Compliance.

               1.   Omrix shall be responsible for assuring that its
                    manufacturing establishments meet applicable requirements to
                    ensure the safety, purity and potency of Omrigam NF,
                    including compliance with all applicable cGMP requirements.

               2.   Omrix shall make its establishments and records available to
                    the FDA and its agents for inspections related to the FDA's
                    consideration and approval of the Omrigam NF BLA. Omrix
                    shall also make samples of Omrigam NF available as requested
                    by the FDA for inspection and assessment.

               3.   Omrix shall assure compliance with any required
                    environmental assessment under 21 CFR Part 25.

     6.3. Omrix shall submit the Omrigam NF BLA to the FDA and be responsible
          for all related communication and correspondence with the FDA. Omrix
          shall promptly inform FFF of all communications with the FDA related
          to the Omrigam NF BLA and provide FFF with copies of all written
          correspondence with the FDA regarding same.

     6.4. Omrix shall be the exclusive owner of the Omrigam NF BLA and, if
          approved by the FDA, Omrix shall be the exclusive owner of the
          biologics license for Omrigam NF (hereafter, the "OMRIGAM NF BIOLOGICS
          LICENSE").

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL     Page 13 of 27

<PAGE>

7.   REGULATORY FILINGS

     7.1. FFF shall be primarily responsible for preparing and paying all fees
          and costs associated with all Regulatory Filings. Omrix shall provide
          FFF with timely assistance and all information necessary to prepare
          Regulatory Filings as required.

     7.2. All correspondence and contact with the FDA related to Regulatory
          Filings and work performed under this Agreement shall be through FFF
          with the exception of the BLA as described in section 6.3 above.

     7.3. Except for data specified under sections 4.4 and 5.3, Omrix shall be
          the exclusive owner of all Regulatory Filings with the exception of
          the BLA and Omrigam NF BL, which shall be owned exclusively by Omrix.

8.   RECORDS

     8.1. Recordkeeping.

          a.   FFF shall keep complete, accurate and current records and
               accounts of work performed under this Agreement.

          b.   Omrix shall keep complete, accurate and current records and
               accounts related to performance of its responsibilities under
               this Agreement.

     8.2. Maintenance of Records. The Parties shall maintain all records and
          accounts related to work performed under this Agreement and all
          Regulatory Filings for at least least two (2) years following
          termination of this Agreement. Thereafter, the parties shall notify
          each other at least sixty (60) days before destroying or discarding
          any records. The party receiving such notice may request that the
          other party send it such records, at the requesting party's expense,
          upon written notice.

9.   INSPECTIONS AND RECALLS

     9.1. Inspections by Omrix.

          a.   FFF shall permit Omrix, at Omrix's expense, to examine FFF's
               records, books, ledgers and records related to work performed
               under this Agreement during regular business hours and with five
               (5) business-day prior written notice. Omrix shall bear the
               expense of such inspections, which shall not exceed one per year.

          b.   FFF shall assure that Omrix shall be permitted during the term of
               this Agreement to conduct monitoring visits of facilities at
               which Clinical Trials are conducted and at which the
               Investigational Drug is distributed under the Treatment Protocol.
               Such monitoring visits shall be conducted at reasonable times
               during normal business hours with reasonable prior written notice
               and shall include inspection of case report forms and related raw
               and clinical data, source documents, informed consent forms and
               other documents for the purpose of confirming compliance with
               regulatory requirements and accuracy of data.

     9.2. Inspection by FFF. Omrix shall permit FFF representatives to inspect
          Omrix's facility and manufacturing processes and to test samples at
          reasonable times during normal business hours with reasonable prior
          written notice for the purpose of confirming compliance with the
          Manufacturing Specifications.

     9.3. Recalls and Withdrawals. At Omrix's request, FFF will recall all
          Investigational Drug distributed by FFF, as soon as practically
          possible. In the event of any recall or withdrawal of the

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL     Page 14 of 27

<PAGE>

          Investigational Drug, whether voluntary (as determined by Omrix in its
          sole discretion) or involuntary, FFF shall be responsible for all
          costs in connection therewith if related to the storage or shipment of
          the Investigational Drug and Omrix shall be responsible for all costs
          in connection therewith in all other situations. In any case,
          following notification of a recall, the Parties will cooperate to
          carry out any required recall.

10.  CONFIDENTIALITY

     10.1. Confidential Information. The Parties agree to protect the
          confidentiality of all "CONFIDENTIAL INFORMATION." For purposes of
          this Agreement, Confidential Information shall include all data and
          information generated or derived as the result of the work performed
          under this Agreement, the terms and existence of this Agreement, all
          Regulatory Filings, Omrix Technology, as defined in Section 1.20,
          above, and any and all materials or information in written, oral, or
          any other form concerning processes, methods, apparatus,
          specifications, products, materials, inventions, literature, patents
          (including applications and rights in either), finances, personnel,
          including any matters not technically or legally considered trade
          secrets, and any other information related to the business or
          activities of any disclosing Party which is not generally known to
          third parties. Confidential Information shall be designated
          "Confidential" when disclosed, provided that, if Confidential
          Information is not marked "Confidential" but, under the circumstances
          surrounding the disclosure, such information should in good faith to
          be treated as Confidential Information, the receiving Party shall
          treat such information as Confidential Information. Confidential
          Information does not include information that:

          a.   Has been in the public domain prior to such disclosure;

          b.   Becomes part of the public domain through no breach of an
               obligation by the receiving Party or its employees;

          c.   Is furnished to the receiving Party by others or by a third party
               who was or is not under an obligation of confidence to the
               disclosing Party at the time of the disclosure to the receiving
               Party;

          d.   Is or can be accurately documented to have been independently
               developed by the receiving Party, provided that information was
               not acquired directly or indirectly from the disclosing Party;
               however, the burden of proving that information disclosed by one
               Party to the other should not be considered "Confidential
               Information" shall be the receiving Party's; or

          e.   Is required to be disclosed pursuant to court order, legal
               proceeding or as required by law or regulation and the receiving
               Party first notifies the disclosing Party of the required
               disclosure.

     10.2. Confidentiality Obligations. The Parties agree to not disclose,
          resell, transfer or use Confidential Information for any purpose other
          than performance of work under this Agreement, without the prior
          written consent of the disclosing Party. This provision shall remain
          in effect throughout the term of this Agreement and for a period five
          (5) years following the termination of this Agreement. The disclosing
          Party's Confidential Information provided to the receiving Party shall
          remain the exclusive property of the disclosing Party and shall be
          returned promptly to the disclosing Party upon written request or upon
          termination or expiration of this Agreement. Upon mutual agreement of
          the Parties, in lieu of returning Confidential Information, a
          receiving Party may destroy Confidential Information and provide
          written certification to the disclosing Party that such destruction
          took place.

     10.3. Permitted Disclosures. Notwithstanding the sections 10.1 and 10.2,
          above, (i) the Parties may, to the extent necessary, disclose and use
          Confidential Information to prepare Regulatory Filings, to obtain a
          Treatment Protocol and approval of a BLA for Investigational Drug, to
          fulfill all regulatory requirements related to work performed under
          this Agreement including, without

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL     Page 15 of 27

<PAGE>

          limitation, correspondence with the FDA, the IRB and officials
          responsible for research compliance at the Clinical Trial and
          Treatment Protocol facilities, and to comply with securities and other
          agency regulations upon advice of counsel and (ii) the Parties may, to
          the extent necessary, disclose Confidential Information to their
          affiliates, attorneys, and accountants, or to any potential investor
          or acquirer of a substantial part of such Party's business (whether by
          merger, sale of assets, sale of stock, or otherwise) that is bound by
          a written agreement to keep such terms confidential, or as may be
          required by law.

11.  INTELLECTUAL PROPERTY

     11.1. Omrix Intellectual Property. All right, title and interest in and to
          all Omrix Intellectual Property, as defined below, shall be the sole
          and exclusive property of Omrix. Nothing in this Agreement should be
          construed to confer upon or grant to FFF any right, title and interest
          therein.

          a.   Under this Agreement, "OMRIX INTELLECTUAL PROPERTY" includes the
               following: Omrix Technology, as that term is defined in section
               1.20; patents, patent applications, patent disclosures and all
               related continuation, continuation-in-part, divisional, reissue,
               reexamination, utility model, certificate of invention and design
               patents, patent applications, registrations and applications for
               registrations; trademarks, service marks, trade dress, Internet
               domain names, logos, trade names and corporate names and
               registrations and applications for registration thereof;
               copyrights and registrations and applications for registration
               thereof; mask works and registrations and applications for
               registration thereof; computer software, data and documentation;
               inventions, trade secrets and confidential business information,
               whether patentable or nonpatentable and whether or not reduced to
               practice, know-how, manufacturing and product processes and
               techniques, research and development information, copyrightable
               works, financial, marketing and business data, pricing and cost
               information, business and marketing plans and customer and
               supplier lists and information; and copies and tangible
               embodiments thereof.

          b.   During the Term of this Agreement, Omrix grants to FFF the right
               and license to use and display Omrix Marks in a manner to be
               approved in advance by Omrix for the exclusive purpose of
               performing the work described in this Agreement. Any such use
               shall inure to the benefit of Omrix and shall be in accordance
               with Omrix's guidelines or other instructions regarding the use
               of the Omrix Marks, which Omrix may modify from time to time at
               its sole discretion. FFF will not make or permit alteration of
               the Omrix Marks or removal or modification of any notices or
               other identifying marks placed by Omrix or its agents on Omrigam
               NF or associated literature. The right granted hereunder is only
               in connection with the use of Omrigam NF as the Investigational
               Drug in the Clinical Trials and under a Treatment Protocol.

          c.   FFF expressly agrees that the name "Omrix," "Omrigam NF" and any
               related designs are the sole property of Omrix. It is further
               understood that there may be in the future other commercial names
               or marks identified with Omrix's products, and that the same are
               the property of Omrix. The said names, designs, and other marks
               are referred to collectively herein as the "OMRIX MARKS" which
               marks Omrix may, in its sole discretion, revise from time to
               time. FFF hereby acknowledges and agrees that Omrix shall retain
               ownership of all intellectual property rights in the Omrix Marks,
               including, but not limited to, any and all, modifications and
               derivatives thereto. All rights not expressly granted to FFF
               herein are reserved by Omrix.

          d.   Upon termination or expiration of this Agreement, FFF shall
               return to Omrix all Omrix Intellectual Property, provided that
               FFF may retain one copy of any documentation if necessary to
               comply with regulatory requirements, and that FFF may, in lieu of
               returning Omrix's Intellectual Property, request permission from
               Omrix to destroy such property and provide written certification
               to Omrix of such destruction.

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL     Page 16 of 27
<PAGE>

     11.2. FFF Intellectual Property. All right, title and interest in and to
          all FFF Intellectual Property, as defined below, shall be the sole and
          exclusive property of FFF. Nothing in this Agreement should be
          construed to confer upon or grant to Omrix any right, title and
          interest therein.

          a.   Under this Agreement, "FFF INTELLECTUAL PROPERTY" includes:
               trademarks, service marks, trade dress, Internet domain names,
               logos, trade names and corporate names and registrations and
               applications for registration thereof; copyrights and
               registrations and applications for registration thereof; mask
               works and registrations and applications for registration
               thereof; computer software, data and documentation; inventions,
               trade secrets and confidential business information, whether
               patentable or nonpatentable and whether or not reduced to
               practice, know-how, manufacturing and product processes and
               techniques, research and development information, copyrightable
               works, financial, marketing and business data, pricing and cost
               information, business and marketing plans and customer and
               supplier lists and information; and copies and tangible
               embodiments thereof.

          b.   Upon termination or expiration of this Agreement, Omrix shall
               return to FFF all FFF Intellectual Property, provided that Omrix
               may retain one copy of any documentation if necessary to comply
               with regulatory requirements, and that Omrix may, in lieu of
               returning FFF's Intellectual Property, request permission from
               FFF to destroy such property and provide written certification to
               FFF of such destruction

12.  PUBLICITY

     During the term of this Agreement, neither Party shall, without the prior
     written consent of the other Party, use the other Party's name, trademark,
     logo, symbol or other image in connection with any products, promotion or
     advertising, nor disclose the existence or substance of this Agreement
     except as required by law or permitted under Section 10.

13.  INDEMNIFICATION

     13.1. Omrix shall indemnify, defend and hold harmless FFF and its
          affiliates and their directors, officers, employees and agents and
          subcontractors from and against any and all losses, damages,
          liabilities, reasonable attorney fees, court costs, and expenses,
          joint or several, as finally determined by court, regulatory agency,
          arbitration or under settlement from third party claims arising out
          of, resulting from, or in any manner caused (i) by breach of this
          Agreement by Omrix or (ii) by Omrix's wilful misconduct or negligence,
          or (iii) by the Investigational Drug due to its condition prior to or
          upon delivery to FFF, or (iv) by infringement of any third party's
          intellectual property relating to the manufacturing, importing, use or
          sale of the Investigational Drug. If the Investigational Drug is, or
          in Omrix's opinion, might be held to infringe as set forth above,
          Omrix may, at its option and cost, replace or modify the
          Investigational Drug so as to avoid infringement, or procure the right
          for FFF to continue the use and sell the Investigational Drug. The
          indemnification set forth in this section 13.1 shall be FFF's sole
          remedy and Omrix's sole liability arising out of Claims of
          infringement.

     13.2. FFF shall indemnify, defend and hold harmless Omrix and its
          affiliates, and their directors, officers, employees and agents and
          subcontractors from and against any and all losses, damages,
          liabilities, reasonable attorney fees, court costs, and expenses,
          joint or several, as finally determined by court, regulatory agency,
          arbitration or under settlement from third party claims arising out
          of, resulting from, or in any manner caused (i) by breach of this
          Agreement by FFF or (ii) by FFF's wilful misconduct or negligence, or
          (iii) by the Investigational Drug due to any modification or
          adulteration of the Investigational Drug occurring after delivery to
          FFF while under FFF's control and possession and prior to delivery to
          an Investigator or treating physician.

     13.3. In the event that either Party seeks indemnification (the
          "INDEMNIFIED PARTY") under the terms of this section, the Indemnified
          Party shall notify the other Party (the "INDEMNIFYING PARTY"), in
          writing, of the action, suit, proceeding, claim, liability, demand or
          assessment giving rise to the

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL     Page 17 of 27

<PAGE>

          claim for indemnification as soon as reasonably practicable after its
          assertion. The Indemnified Party shall permit the Indemnifying Party,
          at the Indemnifying Party's cost, to assume direction and control of
          the defense of the claim, and shall cooperate as requested (at the
          expense of the Indemnifying Party), in the defense of the claim. The
          Indemnified Party shall not settle or otherwise compromise any claims
          or suit without the prior written consent of the Indemnifying Party.

14.  INSURANCE

     14.1. Insurance.

          a.   FFF. FFF shall procure and maintain, at its own expense, in full
               force and effect at all times during this Agreement insurance
               coverage written by a responsible insurance carrier, Best Rated
               A, including general liability, including products liability
               insurance with limits of not less than $10 million ($10,000,000)
               per occurrence and $10 million ($10,000,000) in the aggregate.

          b.   Omrix. Omrix shall procure and maintain, at its own expense, in
               full force and effect at all times during this Agreement
               insurance coverage written by a responsible insurance carrier,
               Best Rated A, including general liability insurance, including
               product liability, with limits of not less than $10 million
               ($10,000,000) per occurrence and $10 million ($10,000,000) in the
               aggregate.

          c.   Clinical Trial Insurance. FFF shall procure and maintain, in full
               force and effect at all times during this Agreement clinical
               trial insurance coverage written by a responsible insurance
               carrier, Best Rated A, with limits of $10 million ($10,000,000)
               per occurrence and $10 million ($10,000,000) in the aggregate.
               The cost of such insurance will be shared equally by the Parties.

          d.   General Requirements. Each Party's insurance policy referred to
               above shall name both Parties hereto as additional insureds and
               will provide for at least thirty (30) days prior written notice
               to the other Party of the cancellation or substantial adverse
               modification thereof. Each Party shall deliver a certificate of
               such insurance to the other Party promptly upon issuance of the
               policy and shall, from time to time as reasonably requested by
               such other Party, furnish such other Party with evidence of the
               maintenance thereof. If any of the insurance policies described
               herein are written on a claims made basis, the applicable party
               maintaining such insurance agrees either to (a) continue to
               purchase such coverage or (b) purchase an extended reporting
               period endorsement ("tail" insurance), in either instance for the
               entire term as defined in section 15.1, below ("TERM") of this
               Agreement, and for a period of two (2) years after the end of
               such Term to cover claims that might arise from the Clinical
               Trials or patients who receive the Investigational Drug under the
               Treatment Protocol.

     14.2. Subject Injuries. Omrix shall be responsible for the cost of
          reasonable and necessary medical care required by any subject or
          patient who receives the Investigational Drug under this Agreement for
          any injury that is the immediate and direct result of use of the
          Investigational Drug ("SUBJECT INJURIES"), excluding costs that arise
          directly from: a) an Investigator's failure to adhere to the terms of
          the Clinical Trial or the Treatment Protocol; or b) negligence or
          willful misconduct on the part of FFF, the CRO or the Investigator.
          FFF shall be responsible for the cost of reasonable and necessary
          medical care for all other Subject Injuries for which Omrix is not
          responsible under this section 14.2.

15.  TERM AND TERMINATION

     15.1. Term. The Term of this Agreement shall begin on the Effective Date
          and shall remain in effect until approval of the Omrigam NF BLA unless
          terminated sooner as provided this section 15.

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL     Page 18 of 27

<PAGE>

     15.2. Termination by Either Party. Either Party may terminate this
          Agreement by giving the other Party written notice if any of the
          following occurs:

          a.   If a Party materially breaches, or materially fails to perform,
               its obligations under this Agreement and fails to cure such
               breach or nonperformance within thirty (30) days after receiving
               written notice thereof, the non-breaching Party in its sole
               discretion may terminate this Agreement upon prior notice to the
               defaulting Party;

          b.   If the Treatment Protocol is not approved within TWO (2) MONTHS
               from when the Treatment Protocol was received by the FDA; or if
               the Treatment Protocol is approved by the FDA and (i) approval is
               subsequently revoked or (ii) the Treatment Protocol is placed on
               clinical hold and the Treatment Protocol cannot be reinstated
               without undue hardship to either Party;

          c.   The FDA withdraws the FFF IND or places the FFF IND on clinical
               hold and the IND cannot be reinstated without undue hardship to
               either Party; or

          d.   The other Party is declared insolvent or bankrupt by a court of
               competent jurisdiction, or a voluntary petition of bankruptcy is
               filed in any court of competent jurisdiction by the other Party,
               or the other Party makes or executes any assignment for the
               benefit of creditors, or a receiver is appointed to control the
               business of the other Party.

     15.3. Termination by FFF. FFF may terminate this Agreement by giving Omrix
          written notice if any of the following occurs:

          a.   FFF's out-of-pocket expenses for conducting the Clinical Trials
               exceeds *** (unless Omrix is willing to bear the excess cost);

          b.   Omrix fails to supply the Investigational Drug in accordance with
               sections 2, 4.3 and 5.2 of this Agreement and Omrix fails to
               remedy such failure within three (3) months of receiving a
               written request from FFF to remedy such failure;

          c.   Approval of the BLA appears unlikely due to the occurrence of a
               serious or life-threatening adverse event, as defined in 21 CFR
               Section 312.32, that is related to the Investigational Drug as
               shipped by Omrix or Omrix has not submitted the BLA within one
               hundred twenty (120) days from the date that FFF has provided
               Omrix with all data under FFF's responsibility necessary for the
               BLA, including all clinical data and the final clinical study
               report;

          d.   On or after September 1, 2007, (i) the BLA has not been approved
               due to the fact that the Clinical Trials have not demonstrated
               the effectiveness of the Investigational Drug or (ii) the BLA has
               not been approved due to adverse regulatory action against Omrix
               or the facility at which the Investigational Drug is manufactured
               or (iii) Omrix has not completed the facility expansion to enable
               the production of *** grams of the Investigational Drug per year;

          e.   If the Treatment Protocol Charge Price is less than *** per gram
               or after FDA approval of the Treatment Protocol but prior to
               approval of the BLA, subject to payment by FFF to Omrix of (a)
               all then outstanding orders issued to Omrix hereunder, plus (b)
               up to a maximum amount of *** for the Investigational Drug
               supplied by Omrix for the Clinical Trials at the Treatment
               Protocol Purchase Price, plus fulfillment of the responsibilities
               set forth in Section 2.9.

     15.4. Effect of Termination. Upon expiration in accordance with section
          15.1, above, or receipt by either Party of written notice of
          termination of this Agreement in accordance with sections 15.2 or
          15.3, (a) the Clinical Trials shall be closed to enrollment and no
          additional Investigational Drug shall be dispensed to enrolled
          subjects or to patients under the Treatment Protocol; and (b) each
          Party shall within thirty (30) days return or destroy all Confidential
          Information in accordance with section 10, above, and Intellectual
          Property in accordance with Section 11, above. Notwithstanding the
          foregoing, upon termination of this Agreement, upon request by

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL     Page 19 of 27

<PAGE>

          Omrix, FFF shall assist Omrix as necessary to transfer to Omrix the
          sponsorship of FFF IND, and all associated contracts (e.g., the CRO
          agreement), and shall provide to Omrix all data and information
          associated with the Clinical Trials and the Treatment Protocol. Upon a
          termination of this Agreement, FFF agrees to transfer ownership of all
          such data and information to Omrix, provided that if FFF terminates
          this Agreement due to the breach of Omrix under Section 15.2.a, then
          the ownership of such data will only be transferred to Omrix upon
          payment by Omrix of FFF's out-of-pocket expenses incurred conducting
          the Clinical Trials.

16.  INDEPENDENT CONTRACTORS.

     The relationship between the Parties established by this Agreement is that
     of independent contractors, and nothing herein shall be construed to
     constitute the Parties as partners, joint venturers, co-owners or otherwise
     as participants in a joint or common undertaking. Neither Party shall have
     any authority to obligate the other in any respect nor hold itself out as
     having any such authority.

17.  LIMITED WARRANTY; LIMITATION OF LIABILITY.

     17.1. Limited Warranty. Omrix warrants that all Investigational Drug will
          materially meet the Manufacturing Specifications, as defined in
          Section 1.17, above, at the time that the Investigational Drug is
          delivered to FFF. EXCEPT AS EXPRESSLY SET FORTH IN THE PRECEDING
          SENTENCE, THE INVESTIGATIONAL DRUG IS PROVIDED "AS IS", AND NO OTHER
          WARRANTIES, EITHER EXPRESSED OR IMPLIED, ARE MADE WITH RESPECT TO THE
          INVESTIGATIONAL DRUG, INCLUDING, WITHOUT LIMITATION THE IMPLIED
          WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.
          FFF'S SOLE AND EXCLUSIVE REMEDY FOR ANY BREACH OF THE FOREGOING
          LIMITED WARRANTY WILL BE, AT OMRIX'S OPTION, REPLACEMENT OF THE
          INVESTIGATIONAL DRUG OR REFUND THE AMOUNT PAID, IF ANY.

     17.2. EXCLUSION OF DAMAGES. EACH PARTY SHALL NOT UNDER ANY CIRCUMSTANCES BE
          LIABLE TO THE OTHER OR ANY THIRD PARTY FOR ANY SPECIAL, INCIDENTAL,
          INDIRECT, PUNITIVE OR CONSEQUENTIAL DAMAGES ARISING IN ANY WAY UNDER
          THIS AGREEMENT OR FROM DEFECTS IN OR USE OF THE INVESTIGATIONAL DRUG
          UNDER ANY THEORY OF LIABILITY, EVEN IF A PARTY IS INFORMED IN ADVANCE
          OF THE POSSIBILITY OF SUCH DAMAGES; PROVIDED THAT THE FOREGOING SHALL
          NOT APPLY TO DAMAGES AWARDED IN THE CASE OF PERSONAL INJURY OR DEATH
          OR FOR BREACH OF CONFIDENTIALITY.

     17.3. LIABILITY CAP. TO THE EXTENT PERMISSIBLE UNDER APPLICABLE LAW, IN NO
          EVENT WILL EITHER PARTY'S LIABILITY IN CONNECTION WITH THE
          INVESTIGATIONAL DRUG OR THIS AGREEMENT EXCEED $10,000,000. THESE
          LIMITATIONS APPLY TO ALL CAUSES OF ACTION IN THE AGGREGATE. THIS
          LIMITATION SHALL NOT APPLY TO AMOUNTS OWING FOR REQUIRED PURCHASES OF
          THE INVESTIGATIONAL DRUG BY FFF UNDER THIS AGREEMENT, INCLUDING AS
          REQUIRED UNDER THE DCI CONTRACT. THE FOREGOING LIMITATIONS IN THIS
          SECTION 17.3 SHALL NOT APPLY TO DAMAGES AWARDED IN THE CASE OF
          PERSONAL INJURY OR DEATH OR INFRINGEMENT UNDER SECTION 13.

18.  ASSIGNMENT AND DELEGATION

     This Agreement may not be assigned by either Party without the prior
     written consent of the other Party, except that either Party shall be
     permitted to assign this Agreement, without the other Party's consent, to
     an affiliate or a company acquiring all or substantially all of the first
     Party's relevant assets, voting stock or business to which this Agreement
     relates, upon written notice to the other Party.

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL     Page 20 of 27

<PAGE>

     Such assignment shall be subject to the assignee agreeing in writing to
     assume the benefits and obligations of this Agreement. Any assignment made
     without prior written consent, if such consent is required, shall be wholly
     void and invalid. If a party is reorganized in such a manner that a
     substantial portion of the assets of the party are transferred to an
     Affiliate, then such party shall require such Affiliate to guaranty the
     performance of such party's obligations under this Agreement. Anything to
     the contrary herein notwithstanding, each Party agrees that the right and
     obligations under this Agreement of the other Party may, from time to time,
     be exercised or performed, as the case may be, in whole or in part by
     Affiliates of such Party; provided that each Party shall remain liable for
     any such obligations delegated to its Affiliates. As used in this section
     18, "Affiliate" means any entity controlled by, controlling, or under
     common control with a party to this Agreement, through ownership or control
     of more than 50% of the voting power of the shares or other means of
     ownership or control, provided that such control continues to exist.

19.  GOVERNING LAW AND VENUE

     This Agreement shall be governed by and construed and enforced in
     accordance with the laws of the State of New York without regard to
     conflict of laws principles. Any action or proceeding arising out of this
     Agreement permitted to be brought in court under section 20.2 will be
     litigated in courts located in New York. Each Party consents and submits to
     the jurisdiction of any local, state, or federal court located in New York
     for this purpose.

20.  DISPUTE RESOLUTION

     20.1. Initial Efforts. The Parties agree to use their best efforts to
          resolve any controversy or claim arising out of or relating to this
          Agreement through good faith negotiations for a thirty (30) day
          period, unless otherwise agreed by the parties.

     20.2. Arbitration. The Parties agree that any dispute, controversy or claim
          that is not resolved under section 20.1, above, shall be settled by
          binding arbitration under the then current Commercial Arbitration
          Rules of the American Arbitration Association. Any such arbitration
          shall be conducted in New York City, in the English language. The
          arbitration shall be conducted by a sole arbitrator who shall be
          appointed by mutual agreement of the Parties. The Arbitrator shall be
          appointed by agreement of the Parties; provided, if the Parties fail
          to agree upon the Arbitrator within thirty (30) days of notice of
          arbitration provided by either Party, the Arbitrator shall be
          appointed by the American Arbitration Association. Upon rendering an
          award or a decision, the Arbitrator shall set forth in writing the
          basis of such award or decision. The Arbitrator's awards and decisions
          shall be final and binding upon the Parties. Judgment on the award or
          any other final or interim decision rendered by the Arbitrator may be
          entered, registered or filed for enforcement purposes in any court
          having jurisdiction thereof. The Parties agree that, any provision of
          applicable law notwithstanding, they will not request, and the
          arbitrator shall have no authority to award, punitive or exemplary
          damages against any Party. The costs of any arbitration, including
          administrative fees and fees of the arbitrator(s), shall be shared
          equally by the Parties, unless otherwise specified by the arbitrator.
          Each Party shall bear the cost of its own attorneys' and expert fees;
          provided that the arbitrator(s) may in their discretion award to the
          prevailing Party the costs and expense incurred by the prevailing
          Party in connection with the arbitration proceeding.

     20.3. Attorney Fees. If any arbitration or litigation is instituted to
          interpret, enforce, or rescind this Agreement, including but not
          limited to any proceeding brought under the US Bankruptcy Code, the
          prevailing Party on a claim will be entitled to recover with respect
          to the claim, in addition to any other relief awarded, the prevailing
          Party's reasonable attorneys' fees and other fees, costs, and expenses
          of every kind.

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL     Page 21 of 27

<PAGE>

21.  WAIVER

     The failure of either Party to assert a right under this Agreement or to
     insist upon compliance with any term or condition of this Agreement shall
     not constitute a waiver of that right or excuse a similar subsequent
     failure to perform any such term or condition by the other Party. The
     observance of any provision of this Agreement may be waived (either
     generally or in any particular instance) only with the written consent of
     the waiving Party.

22.  AMENDMENTS.

     No alteration or amendment of this Agreement, including change in the
     Clinical Trial protocols or the Treatment Protocol, shall be valid unless
     agreed to in writing by both Parties.

23.  SEVERABILITY

     The Parties agree that it is the intention of neither Party to violate any
     public policy, statutory or common laws, and governmental or supranational
     regulations; that if any sentence, paragraph, clause or combination of the
     same is in violation of any applicable law or regulation, or is
     unenforceable or void for any reason whatsoever, such sentence, paragraph,
     clause or combinations of the same shall be inoperative and the remainder
     of the Agreement shall remain binding upon the Parties.

24.  FORCE MAJEURE

     Neither Party shall be liable to the other in damages for, nor shall this
     Agreement be terminable by reason of, any delay or default in such Party's
     performance hereunder, if such delay or default is caused by conditions
     beyond such Party's control including, but not limited to, acts of God,
     war, insurrection, civil commotion, destruction of production facilities or
     materials by earthquake, fire, flood or storm, labor disturbances including
     strikes or lockouts, epidemic or failure of suppliers, public utilities or
     common carriers. Each Party agrees to promptly notify the other Party of
     any event of force majeure under this section 24 and to employ all
     reasonable efforts toward prompt resumption of its performance hereunder
     when possible if such performance is delayed or interrupted by reason of
     such event.

25.  NOTICES

     25.1. All notices and other communications required or desired to be given
          or sent by one Party to the other Party shall be in writing, in the
          English language, and shall be deemed to have been given:

          a.   On the date of delivery, if delivered to the persons identified
               below,

          b.   Five (5) calendar days after mailing if mailed, with proper
               postage, by certified or registered airmail, postage prepaid,
               return receipt requested, addressed as set forth below,

          c.   On the date of receipt if sent by telex or telecopy, and
               confirmed in writing by the person identified in section 25.2,
               below, or

          d.   Two (2) business days after delivered to an internationally
               recognized overnight courier service marked for overnight
               delivery.

     25.2. Notices shall be addressed to the following addresses:

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL     Page 22 of 27

<PAGE>

TO FFF:                                TO OMRIX:

FFF Enterprises, Inc.                  Omrix Biopharmaceuticals, Ltd
41093 County Center Drive              MDA Blood Center,
Temecula, CA 92651                     Tel Hashomer Hospital,
Attn: Patrick M. Schmidt, President    Tel Aviv 52621 Israel
                                       Attn: Robert Taub, President and CEO
Phone: (951) 296-2500
Fax: (951) 296-2565                    Phone: +972 3 531 65 31
Email: pms@fffenterprises.com          Fax: +972 3 535 02 65
                                       Email: robert.taub@omrix.com

With a copy to:                        With a copy to:

Karen N. Winnett, Esq.                 Ronen Bezalel, Adv.
Preston Gates & Ellis LLP              Meitar, Liquornik, Geva & Leshem,
1900 Main Street                       Brandwein
Suite 600                              16 Abba Hillel Silver Road
Irvine, CA 92614                       Ramat Gan 52506
                                       Israel

26.  ENTIRE AGREEMENT

     This Agreement and the Supply and Distribution Agreement: Commercial Phase,
     inclusive of all exhibits, constitutes the entire agreement between the
     Parties with respect to the subject matter hereof and supersedes and
     replaces all prior and contemporaneous agreements, understandings, writings
     and discussions between the Parties. The Parties acknowledge and agree that
     neither of the Parties is entering into this Agreement on the basis of any
     representations or promises not expressly contained herein. It is agreed
     that no usage of trade or other regular practice or method of dealing
     between the Parties hereto shall be used to modify, interpret, supplement,
     or alter in any manner the terms of this Agreement. This Agreement may not
     be changed in any way except by an instrument in writing signed by both
     Parties.

27.  SURVIVAL OF CERTAIN PROVISIONS

     The terms of any section of this Agreement that by their nature survives
     termination or expiration of this Agreement shall survive the termination
     or expiration of this Agreement, including without limitation sections 8
     (Records), 10 (Confidentiality) 11 (Intellectual Property), 13
     (Indemnification), 14 (Insurance), 17 (Limited Warranty; Limitation of
     Liability), 19 (Governing Law and Venue), 20 (Dispute Resolution) and 25
     (Notices).

[Signatures appear on following page.]

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL     Page 23 of 27

<PAGE>

IN WITNESS WHEREOF, the authorized officers of the each of the Parties have
executed this Agreement by their signatures below.

OMRIX BIOPHARMACEUTICALS, LTD.          FFF ENTERPRISES, INC.

By: /s/ Robert Taub                     By: /s/ Patrick M. Schmidt
    ---------------------------------       ------------------------------------
    Signature                               Signature
Name:                                   Name: Patrick M. Schmidt
      -------------------------------   Title: President
Title:                                  Date: December 21, 2005
       ------------------------------
Date:
      -------------------------------

EXHIBITS
Exhibit A. Supply and Distribution Agreement: Commercial Phase
Exhibit B. DCI Contract
Exhibit C. Treatment Protocol Pricing Sheet

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL     Page 24 of 27

<PAGE>

                                    EXHIBIT A

               SUPPLY AND DISTRIBUTION AGREEMENT: COMMERCIAL PHASE

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL     Page 25 of 27

<PAGE>

                                    EXHIBIT B

                                  DCI CONTRACT

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL     Page 26 of 27

<PAGE>

                                    EXHIBIT C

                        TREATMENT PROTOCOL PRICING SHEET

FFF - Omrix Agreement: Investigational Phase      CONFIDENTIAL     Page 27 of 27

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}]]